Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 4/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.44 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.44 |
| ▸ | BUB1 | O43683 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 2/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20521629 | 0.85 | EPHA2 (0.43) | EPHA2PDK1GPR119ERBB2EPHB4 | |
| SCHEMBL24933225 | 0.82 | EPHA2 (0.58) | EPHA2PDK1GPR119ERBB2EPHB4 | |
| SCHEMBL1852171 | 0.81 | PDK1 (0.51) | EPHA2PDK1GPR119ERBB2EPHB4 | |
| SCHEMBL13984286 | 0.81 | PDK1 (0.48) | EPHA2PDK1ERBB2EPHB4P2RX3 | |
| SCHEMBL1848811 | 0.81 | EPHA2 (0.50) | EPHA2PDK1ERBB2EPHB4P2RX3 | |
| SCHEMBL13984639 | 0.81 | EPHA2 (0.50) | EPHA2PDK1ERBB2EPHB4P2RX3 | |
| SCHEMBL306369 | 0.80 | EPHA2 (0.50) | EPHA2PDK1GPR119ERBB2EPHB4 | |
| SCHEMBL9210866 | 0.80 | KDM4E (0.49) | EPHA2PDK1ERBB2EPHB4 | |
| SCHEMBL12661155 | 0.80 | PDK1 (0.49) | EPHA2PDK1GPR119ERBB2EPHB4 | |
| SCHEMBL20521472 | 0.80 | NPSR1 (0.43) | EPHA2PDK1GPR119BUB1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159564-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | iTeos Belgium SA (BE) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159564-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | ADORA2A, ADORA2B, ADORA3 | EPHA2 108/4885PDK1 241/4885GPR119 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.